The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease

International Journal of Biological Markers

Volumn 13, Issue 1, 1998, Pages 10-15

  Van Dalen, A ^a   Barak, V ^b   Cremaschi, A ^c   Gion, M ^d   Molina, R ^e   Namer, M ^f   Stieber, P ^g   Sturgeon, C ^h   Einarsson, R ⁱ  

^a GROENE HART HOSPITAL   (Netherlands)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c TREVIGLIO HOSPITAL   (Italy)

^d Ctro Regionale Specializzato P   (Italy)

^e HOSPITAL CLÍNIC   (Spain)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ BEKI Diagnostics AB   (Sweden)

Author keywords

CA 15 3; CEA; Metastatic breast cancer; TPS

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GROWTH; CANCER REGRESSION; CLINICAL ARTICLE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; PROGNOSIS;

EID: 0031849287     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089801300103     Document Type: Article

References (22)

1. Lamerz R. Circulating tumor markers in breast cancer. Tumor Marker Update 1995; 7: 95-100.
2. Clinical practical guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843-77.
3. Bonadonna G. From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: The experience of the Milan Cancer Institute. Int J Cancer 1993; 55: 1-4.
4. Robertson JFR, Pearson D, Price MR, Selby C, Blamey R, Howel A. Objective measurement of therapeutic response in breast cancer using tumour markers. Br J Cancer 1991; 64: 757-63.
5. Gion M. Serum markers in breast cancer. The Breast 1992; 1: 173-8.
6. van Dalen A. Tumor markers in breast cancer. Ann Chir Gynaecol 1989; 78: 54-64.
7. Dnistrian AM, Schwarz MK, Greenberg EJ, Smith CA, Schwartz DC. CA 15-3 and carcinoembryonic antigen in the clinical evaluation of breast cancer. Clin Chim Acta 1991; 200: 81-94.
8. Safi K, Kohler I, Rottinger F, Berg HG. The value of tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigens. Cancer 1991; 68: 574-82.
9. Jäger W, Krãmer S, Palapelas V, Norbert L. Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest 1995; 55 Suppl 221: 87-92.
10. Rydlander L, Ziegler E, Bergman T, et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 1996; 241: 309-14.
11. Björklund B, Einarsson R. TPS (Tissue Polypeptide Specific Antigen) in oncologic practice: a review with reference to 3000 cases of breast cancer. Tumordiagn u Ther 1996; 17: 67-73.
12. Björklund B. A conceptual approach to tumor antigen in the past and in the future with special reference to TPS. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, eds. Updating on tumor markers in tissues and in biological fluids. Torino: Minerva Medica, 1993; 651-69.
13. Ng JSY, Sturgeon CM, Seth J, Paterson GM, Roulston JE, Leonard RCF. Serological markers for metastatic breast cancer. Dis Markers 1993; 11: 217-23.
14. van Dalen A, Heering KJ, Barak V, et al. Treatment response in metastatic breast cancer. A multicenter study comparing UICC criteria and tumor marker changes. The Breast 1996; 5: 82-8.
15. Blijlevens NMA, Oosterhuis WP, Oosten HR, Mulder HH. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients. Anticancer Res 1995; 15: 2711-6.
16. Haywoardt JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94.
17. Molina R, Zanon G, Filella X, et al. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995; 36: 41-8.
18. Coverney EC, Geraghty JG, Sherry F, et al. The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers 1995; 10: 35-41.
19. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988; 48: 4107-12.
20. Nicolini A, Ferdeghini M, Colizzi C. Evaluation of CEA, TPA, CA 15-3, CA 549 and TPS in the monitoring of metastatic breast cancer. J Nucl Biol Med 1993; 37: 126-33.
21. van Dalen A, van der Linde DL, Heering KJ, Blusse van OudAlblas A. How can treatment response be measured in breast cancer patients? Anticancer Res 1993; 13: 1901-4.
22. Schuurman JJ, Bong SB, Einarsson R. Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 1996; 16: 2169-72.